Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition of dsRNA and astragalus polysaccharide and application thereof

A technology for astragalus polysaccharide and medicine, which is applied in the field of preparation and stability control of the combination medicine, can solve the problems of lack of compatibility of active substances, lack of suitable conditions for double-chain pairing, systematic research on stability influencing factors, etc. The effect of prevention and treatment

Inactive Publication Date: 2010-05-12
青岛汉河动植物药业有限公司
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, although there are domestic production of oligoinosinic acid and oligocytidylic acid raw materials, there is still a lack of systematic research on the suitable conditions for double-strand pairing and factors affecting stability, and there is no compatibility with other active substances. Aspects of reports

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition of dsRNA and astragalus polysaccharide and application thereof
  • Pharmaceutical composition of dsRNA and astragalus polysaccharide and application thereof
  • Pharmaceutical composition of dsRNA and astragalus polysaccharide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach 1

[0015] Specific embodiment one: this specific embodiment adopts the following technical scheme: it is composed of astragalus polysaccharide and dsRNA according to a certain ratio, and the content range of astragalus polysaccharide: 20-50mg / ml; -5mg / ml, molecular weight range: 200-500bp (agarose gel electrophoresis). The main components of the astragalus polysaccharide and dsRNA are prepared according to the production process of the aqueous injection, and the drug combination is obtained after liquid preparation, filtration, potting, sterilization and passing the inspection. Add a certain amount of polyinosinic acid to water for injection to dissolve at 20°C-60°C, then add equimolar polycytidylic acid to dissolve, keep warm for 20-50 minutes, add an appropriate amount of astragalus polysaccharide, mix well, filter , potting, and sterilization.

[0016] The synthesis and drug combination of polymyocytes is to add 0.3 g of sodium pyrosulfite, 0.6 g of sodium chloride and approp...

specific Embodiment approach 2

[0020] Embodiment 2: The drug combination is diluted with water for injection to contain 50 μg / ml of polymyocytes. 160 test chicks were randomly divided into 4 test groups, 40 in each group. Group I: blank control group (physiological saline group); Group II: astragalus polysaccharide drug control group (astragalus polysaccharide injection, 20 mg per kilogram of body weight); Every kilogram of body weight 0.05mg) IV group: drug combination test group (per kilogram of body weight 1ml); The above chicks are isolated and raised in cages, and the blank control group is raised in different chicken houses with the positive control group and the drug test group, and the feeding conditions are kept consistent. After feeding for 10 days, each group was immunized with Newcastle disease vaccine. 21 days after immunization, each group will be treated with drugs according to the grouping plan, and will be challenged after 12 hours (100 units of LD 50 24 hours after the challenge, each gr...

specific Embodiment approach 3

[0023] Embodiment 3: The drug combination is diluted with water for injection to contain 50 μg / ml of polymyocytes. The 40 test piglets were randomly divided into 4 test groups, 10 piglets in each group. The grouping and test methods are as follows: Group I: blank control group (normal saline group); Group II: astragalus polysaccharide drug control group (astragalus polysaccharide injection, 20 mg per kilogram of body weight); Muscle cell injection, 0.05mg per kilogram of body weight) Group IV: drug combination test group (1ml per kilogram of body weight); the weaned piglets were grouped and raised in isolation according to the above experiments, and the feeding conditions were kept consistent. After feeding for 1 week, each group was immunized with classical swine fever vaccine (the immunization dose was the conventional immunization dose). After 21 days of immunization, each group was treated with drugs according to the grouping plan, and challenged after 12 hours (the dose ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition of dsRNA and astragalus polysaccharide and application thereof, in particular to the pharmaceutical composition applied to viral infection prevention and treatment of cultured animals. The pharmaceutical composition is formed by combining the astragalus polysaccharide and the dsRNA according to a certain proportion, wherein the astragalus polysaccharide has the content range of 20-50mg / ml; the dsRNA (polyinosinic acid) has the content range of 1-5mg / ml and the molecular weight range of 200-500bp; and the main components of the astragalus polysaccharide and the dsRNA are processed by matching liquid, filtering, filling and encapsulating as well as sterilizing according to water injection production technology, and the pharmaceutical composition can be obtained after being checked to be qualified. A certain amount of polyinosinic cytidylic acid is added into water for injection and dissolved under the condition of 20-60 DEG C; then, equimolar polycytidylic acid is added into the solution to be dissolved; heat preservation and pairing are carried out for 15-50min; and right amount of astragalus polysaccharide is added, evenly mixed and treated by filtering, filling and encapsulating as well as sterilizing. Therefore, the invention is applicable to improving the immunity of livestock, poultry and aquatic animals, and improves the prevention and treatment for virus diseases.

Description

Technical field: [0001] The invention relates to a drug combination applied to the prevention and treatment of viral infection in farmed animals, in particular to a method for preparing and controlling the stability of the drug for the combination. Background technique: [0002] Viral infection is an important factor that causes the death of farmed animals and affects the economic benefits of animal breeding. With the standardization of national veterinary drug quality standards, a large number of antiviral drugs with original local standards have been cancelled. Demand contradictions are becoming increasingly prominent. [0003] In 1967, Field et al. of Merck Pharmaceutical Company in the United States discovered that enzymatically synthesized double-stranded nucleic acid (double strained RNA, dsRNA) has the ability to induce interferon, wherein the induction of polyinosinic-polycytidylic acid (PIC) It has the strongest ability, it can stimulate the body to produce broad-s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/715A61K31/713A61P31/12A61P37/02
Inventor 刘宗柱尹立杰段坤刘西锋
Owner 青岛汉河动植物药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com